PCK.ASX: R&D Tax Refund, FDA Review of Adult App & Infant App Launch

R&D Tax Refund, FDA Review of Adult App & Infant App Launch

Stock	Painchek Ltd (PCK.ASX)
Release Time	16 Apr 2025, 8:44 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

PainChek Receives R&D Tax Refund, Advances FDA Review, and Launches Infant App

Key Points

$1.41 million R&D tax refund received for FY24
US FDA review of PainChek Adult App advancing, with regulatory clearance anticipated in H1 CY2025
PainChek Infant App launched on Apple App Store, with positive early feedback

Full Summary

PainChek Ltd (ASX: PCK), the developer of the world's first smart device-based pain assessment and monitoring application, has provided updates on its recent activities. The company has received a $1.41 million research and development (R&D) tax refund for the 2024 financial year, which, combined with its recent capital raising, provides PainChek with the cash runway to complete its upcoming key milestones. Regarding the US Food and Drug Administration (FDA) review of the PainChek Adult App, the FDA has requested additional information for clarification, and a meeting is scheduled for April 2025 to discuss these details further. Regulatory clearance would enable PainChek to enter the US healthcare market, which is valued at approximately USD $100 million per annum in aged care alone. PainChek has also officially launched its PainChek Infant app on the Apple App Store, available in Australia for $99.99 per year. The company has implemented a controlled soft launch strategy, prioritizing market learning over immediate scale, which allows it to optimize conversion rates based on real user engagement metrics before expanding to wider market adoption. Feedback on the Infant App has been very positive, with parents valuing the app's ease of use and its ability to provide instant pain scores, offering reassurance and validation during stressful and uncertain moments.

Outlook

PainChek is continuing to gather structured feedback on the Infant App through its partnership with parenting ecosystem Kiindred. Price sensitivity is also being tested more thoroughly, with alternative models like free trials and monthly plans under review. With this foundation of user insight, marketing activity will ramp up in the coming months, including refreshed messaging, updated content, and strategic partnerships with parenting platforms and healthcare experts, all aimed at building awareness and trust to position PainChek Infant as an essential part of the toolkit for a baby's first year.